Axumin Pet Scan For Prostate Cancer

Axumin a 18 f fluciclovine injection is a molecular agent used in positron emission tomography pet imaging in men with suspected recurrent prostate cancer.

Axumin pet scan for prostate cancer. The suspicion is supported by high levels of psa in the blood following prior treatment. The radioisotope used in the australian trial is called gallium 68 ga 68. Axumin consists of a radioactive tracer linked to an amino acid. Psma pet can detect cancer when psa levels are as low as 1 or 2 ng ml.

There is also a kind of pet scan that uses a tracer that binds to an enzyme in prostate cancer cells prostate specific membrane antigen psma. Axumin exploits the fact that prostate cancers absorb amino acids at a much more rapid pace than normal cells. That molecule is linked to a radioactive compound or radioisotope. Food and drug administration fda has approved this injection for use in pet imaging but not for treatment planning in men with biochemically recurrent prostate cancer.

Axumin consists of a radioactive tracer linked to an amino acid. With this in mind researchers aimed to assess the imp. The axumin pet scan works by detecting the metabolic activity of the cancer itself. Axumin is a novel molecular imaging agent indicated for use in pet imaging to identify suspected sites of prostate cancer recurrence in men who have elevated blood levels of prostate specific antigen psa following prior treatment.

A new and better pet. 1 axumin exploits the fact that prostate cancers absorb amino acids at a much more rapid pace than normal cells. In a psma pet ct the tracer used for the pet scan includes a molecule that specifically binds to the psma protein which is often found in large amounts on prostate cancer cells. Axumin based pet ct scans and detection of recurrent prostate cancer posted on april 30 2020 by sitemaster a new report from a relatively small single institution study has provided additional information about the utility of 18 f fluciclovine axumin pet ct scans in the detection of recurrent prostate cancer after definitive first line treatment.

Axumin is used along with a positron emission tomography pet imaging scan for men who have had prior treatment for prostate cancer and now have prostate specific antigen psa levels that are elevated. On may 27 2016 the fda approved a new pet scan tracer injection for prostate cancer patients with suspected prostate cancer recurrence based on elevated prostate specific antigen psa levels following prior treatment 1 there are several names for this new pet imaging agent but they are the same agent. The axumin pet scan works by detecting the metabolic activity of the cancer itself.